BSX — Boston Scientific Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapNeutral

Annual income statement for Boston Scientific, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	8-K
Standards:	USG	USG	USG	USG	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	11,888	12,682	14,240	16,747	20,074
Cost of Revenue
Gross Profit	8,207	8,750	9,918	11,509	13,807
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	10,689	11,227	11,703	14,144	16,461
Operating Profit	1,199	1,455	2,537	2,603	3,613
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,076	1,141	1,985	2,282	3,385
Provision for Income Taxes
Net Income After Taxes	1,040	698	1,592	1,846	2,892
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,040	698	1,593	1,854	2,898
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	985	642	1,570	1,853	2,898
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.11	1.22	1.26	2.01	2.45